Hyperexpression of mitogen-activated protein kinase in human breast cancer.

Mitogen-activated protein (MAP) kinases act as transducers of extracellular signaling via tyrosine kinase-growth factor receptors and G-protein-linked receptors to elements regulating transcription. The activity, abundance, and localization of MAP kinase was investigated in normal and malignant neoplasia of the breast. In carcinoma of the breast, MAP kinase was heavily phosphorylated on tyrosyl residues and its activity elevated 5-10-fold over benign conditions, such as fibroadenoma and fibrocystic disease. By in situ reverse transcription-polymerase chain reaction, hyperexpression of MAP kinase mRNA can be localized to malignant, epithelial cells. Metastatic cells within involved lymph nodes of patients with breast cancer also display hyperexpression of MAP kinase. In spite of persistent activation via phosphorylation, MAP kinase expression is upregulated 5-20-fold and this hyperexpression may be a critical element to initiation as well as the metastatic potential of various forms of human breast cancer.

[1]  E. Goldsmith,et al.  How MAP Kinases Are Regulated (*) , 1995, The Journal of Biological Chemistry.

[2]  G. Nuovo,et al.  Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. , 1995, Cancer research.

[3]  A. Brunet,et al.  [MAP kinase module: role in the control of cell proliferation]. , 1995, Comptes rendus des seances de la Societe de biologie et de ses filiales.

[4]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[5]  A. deFazio,et al.  Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. , 1994, Oncogene.

[6]  G. Nuovo.  PCR in situ hybridization. , 1994, Methods in molecular biology.

[7]  A. Brunet,et al.  Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. , 1994, Oncogene.

[8]  G. Nuovo,et al.  PCR in situ hybridization. , 1994, Methods in molecular biology.

[9]  Jane A. Langdale,et al.  In situ Hybridization , 1994 .

[10]  G. Nuovo,et al.  In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. , 1993, The American journal of pathology.

[11]  J. Blenis,et al.  Signal transduction via the MAP kinases: proceed at your own RSK. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Malbon,et al.  Agonist Regulation of Gene Expression of Adrenergic Receptors and G Proteins , 1993, Journal of neurochemistry.

[13]  L. Heasley,et al.  MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts. , 1992, The Journal of biological chemistry.

[14]  D. Salomon,et al.  Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. , 1992, Cancer treatment and research.

[15]  Mahlon D. Johnson,et al.  Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Brandwein,et al.  Mammalian beta 1- and beta 2-adrenergic receptors. Immunological and structural comparisons. , 1986, The Journal of biological chemistry.